In this Issue
Which emerging concepts will become part of tomorrow's practice?
Medical Editors’ Page
By Allen C. Ho, MD, and Robert L. Avery, MD
Two-year results from the DRCR.net’s Protocol T trial were released at the end of February. How have retina specialists reacted?
By the editors of Retina Today
BUSINESS OF RETINA
PA Avenue Updates
Faced with cuts to retinal detachment reimbursements, the AAO sprang into action.
By George A. Williams, MD
Innovations in Retina
Exposure to certain wavelengths of blue light carries potential blinding effects and a link to AMD.
By Aron Shapiro
Meant to be a forum for new ideas and surgical innovations, the 2016 Vail Vitrectomy meeting did not disappoint. Experts from around the globe shared their expertise and, more so, their thoughts on the future of retina and where it still needs to improve.
By M. Ali Khan, MD
Coding for Retina
Making sense of “incident to” services and diagnostic tests.
By Riva Lee Asbell
The technique preserves the existing IOL and avoids potential complications.
By Sumit P. Shah, MD, and Nicholas D. Chinskey, MD
In a case report, one laser session resolved fluid and improved visual function.
By Rohit Yogi, MD; Mahima Jhingan, MD; and Jay Chhablani, MD
Knowledge is power in treating patients with DME.
By Nancy M. Holekamp, MD
A young woman with no acknowledged white non-Hispanic ancestry received a rare diagnosis.
By Kareem Sioufi, MD; Renelle Pointdujour-Lim, MD; and Carol L. Shields, MD
A review of the features and functions of the Spectralis.
By S.K. Steven Houston III, MD
SPECIAL FOCUS: THE PATIENT PERSPECTIVE
Moving from the informative to the deliberative model.
By Arun Patel, MD, and Mya Aung, MBS, DO, MMed, Sc(Ophth)
COVER FOCUS: Advances in Retina Medicine
The treatment approach has taken aim at its first retinal disease: CMV retinitis.
By Mrinali Gupta, MD, and Szilárd Kiss, MD
Options for managing patients with inherited retinal diseases are becoming more proactive.
By Hershel R. Patel, MS, MD, and David Eichenbaum, MD
An existing cancer drug could offer an alternative treatment to patients with macular diseases.
By Brian C. Joondeph, MD, MPS
Insights gained from ongoing clinical programs will help guide future studies.
By David G. Birch, PhD
David R.P. Almeida, MD, MBA, PhD, is a vitreoretinal surgeon at VitreoRetinal Surgery, PA, in Minneapolis, Minn.